Nu Skin Enterprises starts international tour to roll out its ageLOC anti-aging product portfolio

NewsGuard 100/100 Score

Nu Skin Enterprises, Inc. (NYSE: NUS) today announced the start of an international tour to roll out its ageLOC anti-aging product portfolio, including a new ageLOC edition of its top-selling Galvanic Spa System II. The ageLOC product tour will include stops in more than 20 cities throughout the Americas, Europe and the South Pacific. Nu Skin has also begun rolling out the ageLOC products in Japan, South Korea, China, Hong Kong and Taiwan and will continue its international launch through the summer.

"We continue to fuel enthusiasm for our ageLOC anti-aging products and expect that the addition of the Nu Skin ageLOC Edition Galvanic Spa System II, which we have not previously announced, will generate even greater interest in both our product offering and business opportunity," said Truman Hunt, Nu Skin's president and chief executive officer. "The new ageLOC Galvanic Spa showcases Nu Skin's powerful point of differentiation, integrating the advanced delivery system of galvanic technology with our proprietary ageLOC daily skin care system, to more effectively target the sources of aging by resetting youth gene clusters to a more youthful expression pattern."

"A recent clinical trial revealed that the ageLOC Edition Galvanic Spa boosts the visible benefits of ageLOC Future Serum by an average of 80 percent across multiple signs of aging after just one week," said Joseph Chang, Ph.D., Nu Skin chief scientific officer. "These dramatic results are even more impressive considering that ageLOC Future Serum is clinically shown to begin improving multiple signs of aging on its own in only seven days."

The study was conducted with twice daily application of ageLOC Future Serum – the key product of the ageLOC Transformation skin care system – and three galvanic facials with the ageLOC Edition Galvanic Spa throughout the week.

SOURCE Nu Skin Enterprises, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers identify the most harmful modifiable risk factors for dementia